Knight Therapeutics Inc. (GUD)
Toronto Exchange · Canada · prices in CAD · close of 23 Oct 2026
Key indicators
| Last close | CAD 11.61 |
|---|---|
| 52-week range | 5.66 – 11.83 |
| Return, 1 month / 3 months | +15.1% / +19.8% |
| Return, 1 year / 3 years | +97.8% / +162.7% |
| Trend | Uptrend |
| RSI (14) | 74 |
| Volatility (1 year) | 26.5% |
| Worst drawdown (1 year) | -8.5% |
| Average daily value traded | 0.83M CAD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Knight Therapeutics is a specialty pharmaceutical company based in Montreal, Canada. It acquires, licenses and commercializes prescription medicines, building a portfolio of products that it markets in Canada and in selected Latin American countries. Its medicines address areas such as cancer care, infectious disease and skin conditions, and its customers are mainly physicians, hospitals and pharmacies that use or dispense prescription treatments. The company also provides related services to partners seeking to bring their products into these markets.
On this site Knight Therapeutics Inc. appears as a stock on the Toronto Exchange (Canada), code GUD, with prices in Canadian dollars (CAD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Knight Therapeutics Inc. (GUD) trades on the Toronto Exchange in Canada. It last closed at CAD 11.61 on 23 October 2026.
Its price-based Market X-Ray is 84 out of 100 (a strong price profile), ranking 4 of 870 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 97.8% and over the last three months it rose 19.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Toronto Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 96 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 38.4% | ||
| From 52-week high | -0.8% | ||
| Momentum | 91 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 19.8% | ||
| 6-month return | 55.6% | ||
| 12-month return, skipping the last month | 71.9% | ||
| Stability (higher is calmer) | 86 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -8.5% | ||
| Liquidity | 51 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.83M CAD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +5.2% |
|---|---|
| 1 month | +15.1% |
| 3 months | +19.8% |
| 6 months | +55.6% |
| 1 year | +97.8% |
| 3 years | +162.7% |
| 5 years | +122.0% |
Signals
| 50-day / 200-day average | 10.23 / 8.39 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.27 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Toronto Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.